Is Tarsus Pharmaceuticals, Inc. overvalued or undervalued?

As of 11 May 2021, the valuation grade for Tarsus Pharmaceuticals, Inc. moved from does not qualify to risky, indicating increased caution for investors. The company appears to be overvalued given its high Price to Book Value of 5.39 and negative EV to EBIT and EV to EBITDA ratios of -13.83 and -14.01, respectively. Additionally, the Return on Capital Employed (ROCE) stands at a staggering -1579.81%, further highlighting the company's struggles. In comparison to its peers, Tarsus Pharmaceuticals has a P/E ratio of -26.11, while Amneal Pharmaceuticals, Inc. shows a significantly higher P/E of 48.88, and NewAmsterdam Pharma Co. NV has a P/E of -20.32. The company's stock has performed well over the past year with a return of 65.98%, significantly outpacing the S&P 500's 17.14% return, but its year-to-date performance of -2.43% lags behind the S&P 500's 12.22%. Overall, the combination of poor financial metrics and high valuation ratios suggests that Tarsus Pharmaceuticals is overvalued.